Clinical trial registry record

Metformin in Patients With Unruptured Vertebrobasilar Dissecting Aneurysms (METTLE)

A registered study indexed because it matched monitored longevity research terms. Registry status: Unknown. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Unknown.
Evidence
Registered phase not reported study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated February 6, 2025.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT06405971
Last registry update
February 6, 2025
Status
Unknown
Phase
Phase not reported
Sponsor
Ming Lv
Enrollment
60
Countries
China
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered study indexed because it matched monitored longevity research terms. Registry status: Unknown. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase not reported
Study design
RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE
Evidence population
Human clinical study registration
Participants
60
Population
ALL · 18 Years to 75 Years
Duration
2024-06-01 to 2025-06-01
Intervention
Metformin
Comparator
Placebo group
Outcomes measured
3-dimensional wall enhancement volume rate (3D-WEVR) — 6 months after taking the drug; Morphological changes in VBDAs — 6 months after taking the drug; Characteristic changes in the internal lumen of VBDAs — 6 months after taking the drug; Changes in C-reactive protein — 6 months after taking the drug; changes in serum inflammatory markers — 6 months after taking the drug; Proportion of patients with VBDAs who developed cerebral infarction, transient ischemic attack, cerebral hemorrhage, an…; Wall enhancement index (WEI) — 6 months after taking the drug
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase not reportedA trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Metformin · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology. Source terminology contains a controlled topic term. Summary supplies ageing or longevity context.

Automated source check 100% · update recency 65%. These figures help sort records; they are not medical ratings.

metformin
Read the original source →Export JSON